OSI Pharmaceuticals - Fonds setzen auf den Biotechstar !!!! - 500 Beiträge pro Seite

[blash.de]

Hi Leute,

"...Fondsmanager Vincent Ossipow vom Pictet Biotech-Fonds (WKN 988562) glaubt, daß "OSI-774" ein Star von morgen sein könnte, und Michael Fischer vom Biotechnologie-Beratungsunternehmen Medical Strategy, Kunde ist z.B. der DG Lux Lacuna Apo Biotech (WKN 989696), favorisiert auch OSI Pharmaceuticals..."

MfG www.blash.de

[eddyumbra]

@blash.de

das ist cool. da behalte ich meine osi`s :-) bin bei ca 32 eur
rein, empfehlung biotech strategy brief. dg lux lacuna ist
aber schon "dicke" bei osi pharma dabei, so wie ich weiss.

[habkeingeld]

Hier ein paar Daten über Osi und Fonds Dank an Mitch

Top Mutual Fund Holders of OSIP:
Name des Fonds, Stückanzahl und Wert

Janus Global Life Sciences Fund
954,830 $44,757,656

Smallcap World Fund
480,000 $22,500,000

Fidelity Select Portfolios - Biotechnology
349,700 Stück, Wert: $16,392,188

Royal Canadian Growth Fund
170,000 Stück, Wert: $7,968,750

DFA U.S. 9-10 Small Company Series
139,700 Stück, Wert: $6,548,438

DFA U.S. 6-10 Value Series
91,500 Stück, Wert: $4,289,062

Royal Life Science and Technology Fund
75,000 Stück, Wert: $3,515,625

Munder Framlington Healthcare Fund
75,000 Stück, Wert: $3,515,625

Framlington Health Fund
70,000 Stück, Wert: $3,281,250

Royal Trust American Stock Fund
48,500 Stück, Wert: $2,273,438

Analystenbewertung
Zacks.com: 3 mal Strong buy ==> Note 1
Yahoo: 3 mal Strong buy ==> Note 1

Bei Yahoo steht noch:

Vor 3 Monaten: 1 mal Strong buy und 1 mal Moderat buy
Vor 2 Monaten: 2 mal Strong buy
Vor 1 Monat: 3 mal Strong buy

Nachzulesen auf http://biz.yahoo.com/z/a/o/osip.html

[stoebert]

Hat jemand news zu Osi oder weiss jemand wo aktuelle Daten abzurufen sind!!!!!!!!!!!

[habkeingeld]

Hi stoebert
schau mal auf deren HP http://www.osip.com/welcome oder hier

http://biz.yahoo.com/n/y/y0022.html

http://biz.yahoo.com/n/y/y0005.html

und nun die News von heute

Wednesday September 27, 7:01 am Eastern Time

Press Release

SOURCE: OSI Pharmaceuticals, Inc.

OSI Pharmaceuticals Announces Formal Transfer of IND for OSI-774 And
Provides Clinical Update

UNIONDALE, N.Y., Sept. 27 /PRNewswire/ -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - news) announced today that
Pfizer Inc., has formally transferred the IND dossier for OSI-774 to OSI ahead of schedule with a timeline agreed upon by the parties in their May 23rd agreement.
Rights to OSI-774, were returned to OSI in order for Pfizer to meet Federal Trade Commission requirements for their acquisition of Warner-Lambert Company.
The parties have been cooperating in order to facilitate a smooth transition of data and material to allow OSI to assume full managerial and operational control of the
clinical program for OSI-774. Monitoring and data management responsibilities for the ongoing Phase II studies in non-small cell lung, head and neck and ovarian
cancers now transfer to OSI.

``We are grateful for the tremendous cooperation from our colleagues at Pfizer in facilitating a smooth transfer of the OSI-774 clinical program,`` stated Colin
Goddard, Ph.D., Chairman and Chief Executive Officer, OSI Pharmaceuticals, Inc. ``It`s now our responsibility to ensure that we mount an expeditious and
comprehensive clinical development program for this exciting agent that has the potential to benefit so many cancer patients around the world.``

OSI-774 Clinical Update

With its assumption of management of the complete data set for OSI-774, the Company announced up-to-date preliminary results from the Phase II single agent
study of OSI-774 in head and neck cancer. Three confirmed and two unconfirmed partial responses were seen in the first 24 evaluable patients being treated with
150mg/day of OSI-774 as a monotherapy in the 100 patient study. An additional 9 patients showed evidence of stable disease while 10 patients progressed on the
study. Lillian Siu, M.D., Department of Medical Oncology & Hematology at the Princess Margaret Hospital in Toronto and a lead investigator in the study
commented, ``Our initial findings indicate that OSI-774 is a well tolerated oral medication which is active when administered to patients with advanced head and
neck cancer.`` The acneiform rash, which is apparently characteristic of all the anti-EGFR inhibitors undergoing clinical testing, was reported in approximately 70% of
this first group of patients in the study. Dr. Siu will present a more detailed summary of the trial`s progress at the European Organization for Research and Treatment
of Cancer in Amsterdam on November 9th.

OSI has also seen documented evidence of anti-tumor activity in other EGFR positive tumor types including colorectal and renal cell carcinoma from earlier Phase I
studies in cancer patients with multiple tumor types and in ovarian patients in an on-going Phase II study. ``We are encouraged that we have now seen indications of
single agent activity for OSI-774 in patients with advanced cancers in several different tumor types,`` commented Paul Nadler, M.D., Vice President of Medical
Affairs, OSI Pharmaceuticals, Inc. ``Although OSI-774 is primarily expected to be used in combination with other drugs, these data reinforce the potential value of
this agent in treating cancer patients.``

In preparation for the management of OSI-774`s development, OSI has established a core internal group and a network of external contractors and consultants to
support the program. In addition to Dr. Nadler and his team at Nadler Pharma Associates LLC, OSI has recruited Ms. Christine Boisclair as Director of Regulatory
Affairs. Ms. Boisclair has over 17 years of regulatory experience both in major pharmaceutical companies and more recently at Genzyme Corporation. Theradex®
based in Princeton, New Jersey has been contracted as the Clinical Research Organization to monitor the ongoing clinical studies and McKessonHBOC Clinical &
Biological Services of Rockville, Maryland has been engaged for storage, packaging and distribution of the product. Negotiations are ongoing with a variety of
chemical manufacturers for the further supply of raw materials.

OSI Pharmaceuticals is a leading drug discovery company with a substantial portfolio of product opportunities for commercialization with the pharmaceutical
industry. OSI`s research programs are focused in the areas of cancer therapeutics, respiratory diseases, diabetes, and cosmeceuticals. OSI utilizes a comprehensive
drug discovery and development capability to facilitate the rapid and cost-effective discovery and development of novel, small molecule compounds against more
than 40 gene targets.

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, uncertainties related to the
identification of lead compounds, the successful pre-clinical development thereof, the completion of clinical trials, the FDA review process and other governmental
regulation, pharmaceutical collaborators` competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors
described in OSI Pharmaceuticals` filings with the Securities and Exchange Commission.

Additional information on OSI Pharmaceuticals is available on the World Wide Web at: http://www.osip.com.